Rapid Response to Lenvatinib and Disease Flare After Discontinuation in a Patient With Thymic Carcinoma Harboring KIT Exon 11 Mutation: A Case Report
oleh: Masahiro Torasawa, MD, Tatsuya Yoshida, MD, PhD, Kouya Shiraishi, PhD, Naoko Goto, BS, Toshihide Ueno, PhD, Hitoshi Ichikawa, MD, PhD, Shigehiro Yagishita, MD, PhD, Shinji Kohsaka, MD, PhD, Yasushi Goto, MD, PhD, Yasushi Yatabe, MD, PhD, Akinobu Hamada, PhD, Hiroyuki Mano, MD, PhD, Yuichiro Ohe, MD, PhD
| Format: | Article |
|---|---|
| Diterbitkan: | Elsevier 2024-04-01 |
Deskripsi
Lenvatinib, a multitarget tyrosine kinase inhibitor for c-Kit and other kinases, has exhibited promising efficacy in treating advanced or metastatic thymic carcinoma (TC). Here, we present the case of a patient with metastatic TC harboring a KIT exon 11 deletion and amplification. The patient exhibited a remarkable response to lenvatinib but experienced rapid disease progression after discontinuation of lenvatinib, referred to as a “disease flare.” This case report indicates that KIT mutations and amplification can predict lenvatinib response in patients with TC. However, in such cases, there might be a risk of disease flares after lenvatinib discontinuation.